inno.N's gastroesophageal reflux disease (GERD) therapy, K-CAB, has become a blockbuster drug by surpassing annual sales of 100 billion won ($83.8 million) in just three years of its launch, the fastest among homegrown treatments.

K-CAB’s outpatient prescription totaled 109.6 billion won last year, exceeding 100 billion won for the first time since its launch in 2019. The figure increased 43.9 percent from the 76.1 billion won recorded in 2020.

inno.N also managed to stay on top of the peptic ulcer solvent market for two consecutive years with K-CAB, following 2020.

"K-CAB achieving outpatient prescription sales of 100 billion won in the shortest period among locally developed new drugs is very meaningful as the company has received recognition for the safety and efficacy of its product from the pharmaceutical industry and patients," inno.N CEO Kwak Dal-won said.

Kwak added that the company would further strengthen the market position of the blockbuster drug through expanding its indications, differentiating clinical trials, and developing various formulations.

inno.N plans to launch a new orally disintegrating tablet in the first half-year, in addition to the current tablets, expecting that it will help broaden the scope of K-CAB's market entry and increase market share.

The company has also confirmed the efficacy and safety of long-term administration of K-CAB through a phase 3 clinical trial. It plans to add indications this year based on the study results.

inno.N has exported more than 1 trillion won worth of its products to 26 countries, including a contract to export K-cap technology worth 640 billion won to North America.

The company plans to accelerate its entry into the global market, starting with product approval in China, the second-largest peptic ulcer solvent market after the U.S., in the first half of this year.